NasdaqGM - Nasdaq Real Time Price USD

Vericel Corporation (VCEL)

39.42

-1.45

(-3.55%)

At close: April 22 at 4:00:01 PM EDT

40.40

+0.98

+(2.49%)

Pre-Market: 4:31:53 AM EDT

An Intrinsic Calculation For Vericel Corporation (NASDAQ:VCEL) Suggests It's 47% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$88.20 Vericel's US$46.42...

Simply Wall St. 26 days ago

VCEL
-3.55%
Vericel to Present at Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025Canaccord Genuity 2025 Musculoskeletal Conference on Monday, March 10, 2025Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025 A webcast of the

GlobeNewswire last month

VCEL
-3.55%
Vericel Full Year 2024 Earnings: EPS Beats Expectations

Vericel ( NASDAQ:VCEL ) Full Year 2024 Results Key Financial Results Revenue: US$237.2m (up 20% from FY 2023). Net...

Simply Wall St. last month

VCEL
-3.55%
Vericel Corp (VCEL) Q4 2024 Earnings Call Highlights: Record Revenue and Strong Growth Trajectory

Vericel Corp (VCEL) reports a record fourth-quarter revenue of $75.4 million, achieving 20% annual growth and setting optimistic guidance for 2025.

GuruFocus.com last month

VCEL
-3.55%
Q4 2024 Vericel Corp Earnings Call

Q4 2024 Vericel Corp Earnings Call

Thomson Reuters StreetEvents last month

VCEL
-3.55%
Vericel Corporation (VCEL) Tops Q4 Earnings Estimates

Vericel (VCEL) delivered earnings and revenue surprises of 26.67% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

VCEL
-3.55%
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth Quarter Gross Margin of 78%, Adjusted EBITDA Margin of 40%, and Net Income of $19.8 Million Mid-Term Profitability Targets Increased to Gross Margin in the High-70% Range and Adjusted EBITDA Margin in the High-30% Range Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeon

GlobeNewswire last month

VCEL
-3.55%
High Growth Tech Stocks To Watch In February 2025

Over the last 7 days, the United States market has risen by 1.2%, contributing to an impressive 24% increase over the past year, with earnings forecasted to grow by 15% annually. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in rapidly evolving sectors.

Simply Wall St. last month

VCYT
+1.73%
VCEL
-3.55%
DVAX
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025

CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations s

GlobeNewswire 2 months ago

VCEL
-3.55%
Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Quarterly MACI Implants, Surgeons, and Biopsies Since Launch and Strong Early MACI Arthro Launch Indicators Record Fourth Quarter Gross Margin of Approximately 77% and Adjusted EBITDA Margin of 39% 2025 Total Revenue Guidance of 20% to 23% Growth Mid-Term Profitability Targets Increased to Gross Margin

GlobeNewswire 3 months ago

VCEL
-3.55%
High Growth Tech Stocks To Watch In January 2025

Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and expansion while aligning with broader positive market trends.

Simply Wall St. 3 months ago

EXAS

VCEL
-3.55%
SEMR
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Cor

GlobeNewswire 3 months ago

VCEL
-3.55%
Vericel price target raised to $67 from $61 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Vericel (VCEL) to $67 from $61 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, s

TipRanks 4 months ago

VCEL
-3.55%
High Growth Tech Stocks to Watch in December 2024

Over the last 7 days, the United States market has remained flat, but it has risen by an impressive 28% over the past year, with earnings projected to grow by 15% annually in the coming years. In this environment, high growth tech stocks that demonstrate strong revenue potential and innovative capabilities are particularly noteworthy for investors seeking opportunities in a dynamic sector.

Simply Wall St. 4 months ago

ENFN

GAMB

VCEL
-3.55%
High Growth Tech Stocks To Explore In November 2024

The United States market has experienced a notable upswing, climbing 3.9% over the last week and 33% over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Simply Wall St. 5 months ago

AVPT

AVPTW

OKTA
Vericel Stock Sees RS Rating Shoot Higher

A Relative Strength Rating upgrade for Vericel shows improving technical performance. Will it continue?

Investor's Business Daily 5 months ago

ADMA

VCEL
-3.55%
CPRX
Vericel Third Quarter 2024 Earnings: Beats Expectations

Vericel ( NASDAQ:VCEL ) Third Quarter 2024 Results Key Financial Results Revenue: US$57.9m (up 27% from 3Q 2023). Net...

Simply Wall St. 5 months ago

VCEL
-3.55%
Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ...

Vericel Corp (VCEL) reports a 27% revenue increase and strategic advancements, positioning for sustained growth despite rising expenses.

GuruFocus.com 5 months ago

VCEL
-3.55%
Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates

Vericel (VCEL) delivered earnings and revenue surprises of 60% and 4.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

VCEL
-3.55%
Vericel Reports Third Quarter 2024 Financial Results

Total Revenue Growth of 27% to $57.9 Million Gross Margin of 72% and Adjusted EBITDA Growth of 84% Full-Year Profitability Guidance Raised FDA Approval and Commercial Launch of MACI Arthro in Third Quarter Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarte

GlobeNewswire 5 months ago

VCEL
-3.55%

Performance Overview

Return	VCEL	S&P 500 (^GSPC)
YTD	-28.21%	-10.10%
1-Year	-13.13%	+5.53%
3-Year	+11.36%	+23.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vericel Corporation (VCEL)

An Intrinsic Calculation For Vericel Corporation (NASDAQ:VCEL) Suggests It's 47% Undervalued

Vericel to Present at Multiple Upcoming Investor Conferences

Vericel Full Year 2024 Earnings: EPS Beats Expectations

Vericel Corp (VCEL) Q4 2024 Earnings Call Highlights: Record Revenue and Strong Growth Trajectory

Q4 2024 Vericel Corp Earnings Call

Vericel Corporation (VCEL) Tops Q4 Earnings Estimates

Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

High Growth Tech Stocks To Watch In February 2025

Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025

Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets

High Growth Tech Stocks To Watch In January 2025

Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Vericel price target raised to $67 from $61 at Truist

High Growth Tech Stocks to Watch in December 2024

High Growth Tech Stocks To Explore In November 2024

Vericel Stock Sees RS Rating Shoot Higher

Vericel Third Quarter 2024 Earnings: Beats Expectations

Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ...

Vericel Corporation (VCEL) Reports Q3 Loss, Tops Revenue Estimates

Vericel Reports Third Quarter 2024 Financial Results

Performance Overview